FDA Approves LEADOPTIK’s Innovative System to Enhance Lung Biopsy Accuracy

The United States Food and Drug Administration (FDA) has granted 510(k) clearance to LEADOPTIK’s innovative Last Inch Assessment™ (LIA) system, aimed at enhancing the accuracy of lung biopsy procedures. This landmark decision allows for the integration of high-resolution imaging directly into biopsy tools, a significant advancement in the field of respiratory medicine.

George Cheng, MD, from the UC San Diego School of Medicine and a member of LEADOPTIK’s Clinical Advisory Board, emphasizes the importance of this technology. He stated, “The LIA system represents the missing link in the bronchoscopy workflow.” By incorporating depth imaging into the biopsy tool, this system allows physicians to visualize and characterize lung tissue in real-time, addressing the limitations of current workflows that rely on external imaging or post-procedure validation.

The LIA system utilizes proprietary silicon metamaterials, providing imaging resolution up to 50 times better than existing technologies. Ali Sadoughi, MD, from Albert Einstein College of Medicine and another advisory board member, highlighted the critical nature of this advancement. “The ‘last inch’ is where the path to timely intervention is ultimately determined,” he noted. “Confirming that the needle has sampled the correct tissue is the critical missing step.”

According to Reza Khorasaninejad, CEO and Co-Founder of LEADOPTIK, the preclinical data supporting this FDA clearance is promising, indicating biopsy accuracy exceeding 95%. He remarked, “We are in a uniquely strong position to address one of the most critical unmet needs in lung cancer diagnostics.” As they prepare for hospital deployment, the focus remains on empowering physicians with real-time insights that could accelerate diagnosis and improve patient outcomes.

Lung cancer is the leading cause of cancer-related death globally, responsible for nearly 1.8 million deaths annually. Timely diagnosis is essential for improving treatment outcomes, yet many patients continue to fall through the cracks in the healthcare system. Mary Pasquinelli, DNP, who directs the lung screening program at UI Health in Chicago, previously discussed the impact of screening. She stated, “We know we can reduce lung cancer mortality by 20 to 25% with screening. We just have to get them screened.”

Pasquinelli’s team employs a hybrid model that integrates centralized coordination with primary care to enhance lung cancer screening rates. They proactively monitor low-dose CT (LDCT) orders, directly reach out to patients, and ensure adherence to follow-up scans. This comprehensive approach includes shared decision-making visits, which serve as an initial educational touchpoint for patients at risk of lung cancer.

“Many of my patients are anxious,” she explained. “But I sit down and explain what pulmonary nodules are and what the scan does and doesn’t show.” This patient-centered approach fosters understanding, alleviating fears and encouraging participation in screening.

The introduction of the LIA system has the potential to transform lung biopsy procedures significantly. By providing real-time imaging capabilities, it aims to improve diagnostic accuracy and ensure that critical tissue sampling occurs effectively. As LEADOPTIK prepares for a limited launch, the medical community eagerly anticipates the impact of this groundbreaking technology on lung cancer diagnostics and patient care.